Stephen Ray Mitchell

CIK: 0001802653

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (40.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VNDA

Vanda Pharmaceuticals Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VNDA
Vanda Pharmaceuticals Inc.
Jun 4, 2026
Award(A)
Direct
41.6K shares-
VNDA
Vanda Pharmaceuticals Inc.
May 18, 2026
Gift(G)
Direct
25.8K shares-
VNDA
Vanda Pharmaceuticals Inc.
Jun 13, 2025
Sale(S)
Direct
7K shares at avg. $4.59$32K
VNDA
Vanda Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Direct
59.2K shares-
VNDA
Vanda Pharmaceuticals Inc.
Nov 14, 2024
Sale(S)
Direct
5K shares at avg. $5.17$26K

		Type	Shares	Price		Ownership
Jun 4, 2026	VNDA Vanda Pharmaceuticals Inc.	Award(A)	41,600	-	$0	Direct
May 18, 2026	VNDA Vanda Pharmaceuticals Inc.	Gift(G)	25,836	-	$0	Direct
Jun 13, 2025	VNDA Vanda Pharmaceuticals Inc.	Sale(S)	7,000	$4.59	$32,130	Direct
Jun 5, 2025	VNDA Vanda Pharmaceuticals Inc.	Award(A)	59,225	-	-	Direct
Nov 14, 2024	VNDA Vanda Pharmaceuticals Inc.	Sale(S)	5,000	$5.17	$25,863	Direct

1-5 of 5 transactions

About Mitchell Stephen Ray

Mitchell Stephen Ray (SEC CIK 0001802653) files insider reports with the SEC as Director of Vanda Pharmaceuticals Inc. (VNDA).

Signal8 holds 5 ownership filings by Mitchell Stephen Ray, all Form 4s, filed between Nov 18, 2024 and Jun 8, 2026. Those filings report 5 transactions, from Nov 14, 2024 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mitchell Stephen Ray's filings is in WASHINGTON, DC.

Recent filings by Mitchell Stephen Ray

Jun 4, 2026: Grant or award of VNDA shares (Form 4, code A).
May 18, 2026: Gift of VNDA shares (Form 4, code G).
Jun 13, 2025: Open-market sale of VNDA shares (Form 4, code S).
Jun 5, 2025: Grant or award of VNDA shares (Form 4, code A).
Nov 14, 2024: Open-market sale of VNDA shares (Form 4, code S).

Other insiders filing for Vanda Pharmaceuticals Inc. (VNDA)

McGuire Daniel Patrick, SVP, GC and Secretary
Chrousos Phaedra, Director
Duncan Charles Cliff, Director
DUGAN RICHARD W, Director
Ward Anne Sempowski, Director
Honore Tage, Director

How to read Form 4 transaction codes